Conducted between June 2011 and March 2013 at 191 sites in 27 countries in Europe, North America, South America, Asia, and Australia this was a randomised, placebo-controlled trial designed to evaluate the efficacy and safety of 3mg liraglutide 'injected subcutaneously once daily, as an adjunct to a reduced-calorie diet and increased physical activity, for weight management in overweight or obese adults who did not have diabetes at baseline.' A total of 3,731 individuals participated in the trial, of whom 2,487 were assigned to lifestyle intervention plus liraglutide and 1,244 to lifestyle intervention with a placebo
If Im being honest, this is the one that saves me from raiding my kitchen later
GLP-1 receptor agonists present a viable alternative, especially for patients unable to tolerate CPAP therapy or those seeking additional support alongside traditional methods
: The EU approval strengthens Novo Nordisk's #obesity portfolio by expanding #patient #choice with both #oral and #higher-dose #injectable options, while increasing #competitive #pressure in the emerging #oral GLP-1 market
Read More: What Is the Best NAC Supplement
/product/99/7475523/2.jpg?7369)
